Physician profile
Michelle K Atchison
NPI 1659563039
$3,305.34
in general payments reported to CMS, 2019-2025
26 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $101 · 2021: $398 · 2022: $396 · 2023: $267 · 2024: $549 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.12 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,315.60 | 2019-2025 | Clareon, Rocklatan, Eysuvis |
| Mallinckrodt Hospital Products INC. | $380.82 | 2021-2024 | Acthar |
| Abbvie INC. | $219.38 | 2021-2025 | Durysta |
| Horizon Therapeutics Plc | $176.25 | 2021-2023 | Tepezza |
| Dompe US, INC. | $164.41 | 2020-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $149.22 | 2020-2025 | Cequa |
| Oyster Point Pharma, INC. | $89.46 | 2022-2024 | Tyrvaya |
| Genentech USA, INC. | $87.94 | 2024-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $83.91 | 2021-2023 | |
| Rxsight INC | $77.19 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Astellas Pharma US INC | $73.48 | 2023-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $61.74 | 2025 | Xdemvy |
| The Cameron-Ehlen Group, INC. | $58.95 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $56.62 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $39.49 | 2022-2025 | Miebo, Xiidra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $35.25 | 2022-2025 | Istent Infinite, Idosetr |
| Johnson & Johnson Surgical Vision, INC. | $34.69 | 2021-2024 | Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $33.36 | 2020-2021 | |
| Amgen INC. | $29.95 | 2025 | Tepezza |
| Allergan, INC. | $28.06 | 2021 | |
| Apellis Pharmaceuticals, INC. | $21.34 | 2023 | Syfovre |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $19.20 | 2019 | |
| Harrow Eye, LLC | $16.68 | 2025 | Vevye |
| Biotissue Holdings INC. | $16.49 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Atchison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.